- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Bothell Today
By the People, for the People
MIRA Pharmaceuticals and Athira Pharma Compared in New Analysis
Two small-cap biotech firms face off as analysts assess their prospects
Mar. 16, 2026 at 8:52am
Got story updates? Submit your updates here. ›
A new analysis from Transcript Daily compares MIRA Pharmaceuticals (NASDAQ:MIRA) and Athira Pharma (NASDAQ:ATHA), two small-cap biotech companies developing treatments for neurological and psychiatric disorders. The article examines factors like valuation, institutional ownership, profitability, and analyst recommendations to determine which stock may be the better investment.
Why it matters
As small-cap biotech firms, MIRA and Athira represent high-risk, high-potential investment opportunities in the rapidly evolving neuroscience drug development space. Understanding the relative strengths and weaknesses of these two companies can help investors make informed decisions about allocating capital in this competitive and volatile sector.
The details
The analysis finds that Athira Pharma has stronger institutional ownership at 57.1% compared to MIRA's 35.2%, as well as higher insider ownership at 19.8% versus 6.7% for MIRA. Athira also trades at a lower price-to-earnings ratio, indicating it may be more undervalued. However, MIRA's lead drug candidate, Ketamir-2, is further along in development than Athira's lead asset, fosgonimeton. The article also notes that Athira has a higher beta of 2.79 compared to MIRA's 1.78, making it more volatile. Overall, the analysis suggests that while both companies have promise, Athira may be the more favorable investment based on the factors examined.
- The analysis was published on March 16, 2026.
The players
Athira Pharma
A late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegradation, with lead candidate fosgonimeton in Phase 2/3 trials for Alzheimer's disease.
MIRA Pharmaceuticals
A pre-clinical-stage pharmaceutical development company with two neuroscience programs, including the oral ketamine analog Ketamir-2 and the oral pharmaceutical marijuana MIRA-55, both under investigation for various neurological and psychiatric disorders.
The takeaway
This analysis highlights the competitive landscape and high-risk, high-potential nature of the small-cap biotech sector, where companies like Athira and MIRA are vying to develop innovative treatments for complex neurological and psychiatric conditions. Investors will need to carefully weigh the relative strengths and weaknesses of each firm to determine which may offer the best long-term growth potential.
